Baillie Gifford & Co
ACAD icon

Baillie Gifford & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Baillie Gifford & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-618
Closed -$11.6K – 297
2023
Q1 		$11.6K Buy
618
+74
+14% +$1.41K ﹤0.01% 386
2022
Q4 		$8.66K Hold
544
– – ﹤0.01% 421
2022
Q3 		$9K Hold
544
– – ﹤0.01% 415
2022
Q2 		$8K Hold
544
– – ﹤0.01% 428
2022
Q1 		$13K Hold
544
– – ﹤0.01% 414
2021
Q4 		$13K Hold
544
– – ﹤0.01% 420
2021
Q3 		$9K Hold
544
– – ﹤0.01% 452
2021
Q2 		$13K Hold
544
– – ﹤0.01% 401
2021
Q1 		$14K Buy
544
+12
+2% +$528 ﹤0.01% 367
2020
Q4 		$28K Buy
+532
New +$26.4K ﹤0.01% 297

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baillie Gifford & Co's ACAD Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 618 shares — an estimated $11.6K sold.

Baillie Gifford & Co first reported a position in ACAD in Q4 2020 and held it in 10 quarters. The position peaked at $28K in Q4 2020. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 618 Acadia Pharmaceuticals shares in Q2 2023, an estimated $11.6K.
  • Baillie Gifford & Co first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Acadia Pharmaceuticals position peaked at $28K in Q4 2020.
  • 236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.